Examining the Future: Ocugen's Earnings Outlook
Benzinga Insights 8 months ago
Earnings
Ocugen (NASDAQ:OCGN) is set to give its latest quarterly earnings report on Wednesday, 2026-03-04. Here's what investors need to know before the announcement.
Analysts estimate that Ocugen will report an earnings per share (EPS) of $-0.06.
Ocugen bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Overview of Past Earnings
The company's EPS missed by $0.02 in the last quarter, leading to a 2.13% drop in the share price on the following day.
Here's a look at Ocugen's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.05 | -0.06 | -0.05 |
| EPS Actual | -0.07 | -0.05 | -0.05 | -0.05 |
| Price Change % | -2.13 | -3.53 | -2.81 | 9.96 |
Performance of Ocugen Shares
Shares of Ocugen were trading at $1.94 as of March 02. Over the last 52-week period, shares are up 225.42%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Unveiling the Story Behind Ocugen
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Unraveling the Financial Story of Ocugen
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Ocugen's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 54.23%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ocugen's net margin excels beyond industry benchmarks, reaching -1144.46%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ocugen's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -608.99%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -36.07%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ocugen's debt-to-equity ratio surpasses industry norms, standing at 9.33. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
To track all earnings releases for Ocugen visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.